Combining ublituximab with the novel PI3K inhibitor TGR-1202 for CLL
TGR-1202 in CLL and non-Hodgkin lymphoma
Novel venetoclax combination therapy advancing the field of CLL
Where are we with precision medicine for CLL?
The importance of educating patients about adverse effects of treatment